- 期刊
- OpenAccess
翼狀贅肉手術很使用Mitomycin C與Thiotepa的比較
A Comparison of Using Mitomycin C and Thiotepa for Medical Treatment of Postoperative Pterygium
摘要
本文收集近兩年內基隆長庾醫院原發性真狀贅肉的病例105人（120眼），及再發性的8人（8眼），施行鞏膜暴露法；單眼手術病例術技以Mitomycin C治療；其中有15個（30眼）原發病例，兩眼均接受手術，術後一眼以Mitomycin C治療，另一眼以Thiotepa治療，所有手術均追蹤3個月以上，並統計其再發率及併發症做比較。 原委性的105人（男58，女47），平約年齡為52歲，單眼施行手衍的90人（90眼），有8人（8眼）再委，而雙眼手術的15人（30眼），使用Mitomycin C的15眼均無再發，而使用Thiotepa的15眼有3眼再發；合計使用Mitomycin C的再發率為7.6% (8/105)，而使用Thiotepa的20% (3/15)。再發性的8人（男5，女3），平均年齡為48歲，8眼中有2眼再發，再發率為25%。在併發症方面：結膜充血的比例以使用Mitomycin C組的較明顯，另外有5例表在性點狀角膜炎，2例肉芽腫，1例類疱疹性虹彩角膜炎復發，及2例鞏膜潰瘍均在Mitomycin C組產生。
關鍵字
無資料並列摘要
To compare the effect of Mitomycin C and Thiotepa in preventing the recurrence of postoperative pterygium, these two different medications were used respectively after pterygium excision with bare scleral method in 105 patients (120 eyes) with primary pterigia and in 8 patients (8 eyes) with recurrent pterygia. Mitomycin C (0.4 mg/cc) was used in 105 primary pterygia and 8 recurrent pterygia, while Thiotepa (1 mg/cc) was used in the second operated eye of 15 both-eye-surgery primary cases. All cases were followed up for at least 3 months. The recurrent rate of Mitomycin C for primary cases was 7.6% (8/105) and for recurrent cases was 25% (2/8). The recurrent rate of Thiotepa was 20% (3/15) for primary cases. The comparison of these two different treatment in the different eyes of a single patient was statistically significance (p＜0.05), that is 20% (3/15) in Thiotepa versus 0% (0/15) in Mitomycin C. However 3 cases of corneoscieral ulcer was noted in Mitomycin C treated group, and none occurred in Thiotepa treated group.